Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT162b2 + seasonal inactivated influenza vaccine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
BNT162b2 + seasonal inactivated influenza vaccine refers to the coadministration of the Pfizer-BioNTech COVID-19 mRNA vaccine (Comirnaty) and a standard seasonal inactivated influenza vaccine (SIIV). This regimen was evaluated in Phase 3 clinical trials, such as NCT05310084, to determine the safety and immunogenicity of simultaneous administration in adults. BNT162b2 is a nucleoside-modified mRNA vaccine formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein, providing protection against COVID-19. The SIIV component consists of inactivated influenza virus particles or subunits designed to protect against circulating seasonal flu strains. Clinical data from these trials demonstrated that coadministration elicited noninferior immune responses compared to separate administration, with an acceptable safety profile, supporting the feasibility of simultaneous vaccination for both respiratory pathogens.
- Other names
- BNT162b2 + SIIVComirnaty + SIIVPfizer-BioNTech COVID-19 vaccine + SIIV
02
Targets
HA (Hemagglutinin)SARS-CoV-2 spike
Beyond the preview
Go deeper on BNT162b2 + seasonal inactivated influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT162b2 + seasonal inactivated influenza vaccine.